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Abstract
Background: The reticular basement membrane (Rbm) in smokers and especially smokers with COPD is
fragmented with “clefts” containing cells staining for the collagenase matrix-metalloproteinase-9 (MMP-9) and
fibroblast protein, S100A4. These cells are also present in the basal epithelium. Such changes are likely hallmarks of
epithelial mesenchymal transition (EMT). We aimed to confirm the epithelial origin of these Rbm cells, and to
exclude potential confounding by infiltrating inflammatory cells.
Methods: Endobronchial biopsy sections from 17 COPD current smokers, with documented Rbm splitting and
cellularity were stained for neutrophil elastase (neutrophil marker), CD68 (macrophage/mature fibroblasts), CD4+/CD8
+ T lymphocytes, CD19 (B-cells), CD11c (dendritic cells/inflammatory cells), and S100 (Langerhans cells). The number
of cells in the Rbm and epithelium staining for these “inflammatory” cell markers were then compared to numbers
staining for S100A4, “a documented EMT epitope”. Slides were double stained for S100A4 and cytokeratin(s).
Results: In the basal epithelium significantly more cells stained for S100A4 compared to infiltrating macrophages,
fibroblasts or immune cells: median, 26 (21.3 - 37.3) versus 0 (0 - 9.6) per mm, p < 0.003. Markedly more S100A4
staining cells were also observed in the Rbm compared to infiltrating macrophages, neutrophils, fibroblasts or
immune cells or any sub-type: 58 (37.3 - 92.6) versus 0 (0 - 4.8) cells/mm Rbm, p < 0.003. Cells in the basal
epithelium 26 (21.3 - 37.3) per mm) and Rbm (5.9 (2.3 - 13.8) per mm) frequently double stained for both
cytokeratin and S100A4.
Conclusions: These data provide additional support for active EMT in COPD airways.
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Introduction
One of the features of chronic inflammatory airway dis-
eases, including COPD, is airway remodelling [1]. In
COPD, remodelling may occur as a response to smok-
ing-induced damage to the airways, [2-4] but the details
of structural changes and underlying mechanism are
poorly described or understood. One potential mechan-
ism contributing to airway fibrosis is transition of airway
epithelial cells to a mesenchymal phenotype with
myofibroblast characteristics, which then migrate into
the lamina propria, a process termed epithelial mesench-
ymal transition (EMT) [5,6]. There is little knowledge
regarding the potential for EMT to occur in COPD
airways.
In a recently published study, [7] we provided preli-
minary data suggesting that EMT is indeed likely in
smokers’ airways, but is especially active in the airways
in current smoker - COPD subjects. These findings
were based on ‘classic’ cell marker staining as used in
other publications regarding EMT [8-12]. As a likely
hallmark of EMT, we showed that the reticular base-
ment membrane (Rbm) in smokers and COPD is highly
fragmented, with elongated spaces or cracks, which we
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any medium, provided the original work is properly cited.termed “clefts” [7,13], again typical of EMT as described
in the literature [10-12,14,15]. These elongated spaces
and cracks or clefts in the Rbm were often not empty,
but frequently contained cells, which we found were
positive for the mesenchymal markers S100A4, vimentin
and MMP-9. MMP-9 is a type IV collagenase, which
increases in abundance during the process of EMT.
Functionally MMP-9 is thought to assist epithelial cell
migration by disrupting underlying basement membrane
and Rbm and likely to be responsible for the Rbm frag-
mentation and cleft formation.
Although these changes which we have described are
consistent with the presence of active EMT, we need
further confirmation; in particular that the Rbm cells we
have noted as expressing mesenchymal markers also
express epithelial markers. It is also possible that the
cell data could be confounded by us staining inflamma-
tory cells infiltrating from below, which could be those
positive for S100A4 and MMP-9.
In order to provide furthere v i d e n c eo fap o t e n t i a l
epithelial origin of cells in the Rbm of smoking COPD
subjects, we have undertaken double immunostaining
with both an epithelial and mesenchymal marker (cyto-
keratin-(s) and S100A4, respectively). S100A4 may also
be expressed at least weakly by some inflammatory cells
[16,17]. We therefore, immunostained biopsies from
smoker COPD patients for neutrophils, macrophages,
fibroblasts, CD4+ and CD8+ lymphocytes, B cells and
also dendritic cells and Langerhans cells.
Since our previous observations had shown that the
putative changes of EMT were most marked in actively
smoking COPD subjects, this confirmatory “proof-of-
concept” study was limited to this most relevant clinical
phenotypic group. We have previously studied normal
controls and smokers with normal lung function as
comparator groups [7], and the latter group also show
similar Rbm changes but to a lesser extent., but there
seemed little reason to include them in this follow up.
Where we focus on where the signal is greatest.
Methods
Subjects
In this study stored biopsies were selected from 6 of the
seventeen COPD current smokers (COPD-CS) pre-
viously recruited using GOLD criteria [18]; all had
signed informed consent for ongoing analysis of their
biopsies (approved by the Human Research Ethics Com-
mittee Tasmania Network). Subjects with a history of
other respiratory disorders were excluded. No subjects
were receiving corticosteroids (oral or inhaled). These 6
chosen were not exception in any way from the COPD
g r o u pa saw h o l e ,b u ta l lh a dt h et y p i c a lC O P Db i o p s y
appearance that we have interpreted as likely airway
mucosal EMT.
Bronchoscopy
Endobronchial biopsies were taken from near sub-seg-
mental carinae of the right lower lobe (using alligator
forceps, FB-15C; Olympus, Tokyo) [19].
Immunostaining
Paraffin embedded sections of 3 μma n d5 0μma p a r t
mounted on each slide. At room temperature (RT) sec-
tions were stained with the following antibodies: anti-
CD11c monoclonal (dendritic cells/inflammatory cells)
(Abcam, cat no. ab52632, at 1:20,000 for 2 hours at RT),
anti-CD4/CD8 monoclonal antibodies (Novocastra, cat
no. NCL-CD4-IF6/cat no. NCL-CD8-4B11, at 1:15 for 2
hours), anti-CD68 monoclonal (macrophages and
mature fibroblasts) (Dako, cat no. M0814, at 1:500 for
30 minutes), anti-CD19 monoclonal (B-cells) (Abcam,
cat no. Ab31947, at 1:8000 for 2 hours), anti-neutrophil
elastase monoclonal (Dako, cat no. Ab31947, at 1:500
for 1 hour), anti-S100 polyclonal (Langerhans cells)
(Dako, cat no. Z0311 at 1:3000 for 1 hour) and anti-
S100A4 polyclonal (Dako, cat no. A5114, 1:2500 for 90
minutes). Antibodies were visualised using horseradish
peroxidase (HRP) conjugated DAKO Envision plus
reagent (cat no. K4001, anti-mouse or K4003 anti-rab-
bit) and diaminobenzidine (DAB) for colour resolution
(brown).
Double-staining for cytokeratin and S100A4 was per-
formed using an anti-pan-cytokeratin monoclonal anti-
body (Dako, cat no. M3515 at 1:50 for 1 hour) and then
secondarily bound using Dako “Real” (cat no. K5005)
alkaline phosphatase reagent and visualised using Dako
(cat no. K0640) liquid permanent red (mayer’sh a e m a -
toxylin was added at this point to elaborate nuclei) this
was followed by the anti S100A4 polyclonal antibody
(1:2000 for 90 minutes) that was visualised using HRP
conjugated DAKO Envision plus (cat no. K4003) reagent
and vina green for colour resolution (10 minutes at RT,
Biocare, cat no. VG807 H, L). For the negative controls,
matched sequential sections were stained with primary
antibody replaced with a species-appropriate IgG1 at
equivalent dilutions and conditions. We have published
using these methods [7,13,19,20].
Biopsy analysis and quantitation
Computer-assisted image analysis was performed (Leica
DM 2500 microscope, Microsystems, Germany), Spot
insight 12 digital camera and Image Pro V5.1 (Media
Cybernetics, USA) software. For this analysis, we used
representative sections (n = 6) from 17 different COPD
current smokers for each of the markers of interest. All
slides were counted in a single batch by a single experi-
enced observer (SS) with quality assurance on randomly
selected slides provided by a professional academic
pathologist (HK).
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After all counting had been completed, the data were
analysed. As data were not normally distributed, results
are presented as medians and ranges for cells in the
basal epithelium and Rbm stained for each marker
respectively, and analysed relative to S100A4 cell stain-
ing. Comparisons between different markers were
undertaken using the Mann Whitney U test. Associa-
tions between variables were assessed using Spearman’s
rank test. Statistical analyses were performed using SPSS
15.0 for Windows, 2003, with a two-tailed P-value ≤
0.05 being considered significant.
Results
Demographics of participants are presented in Table 1.
Confirming epithelial origin of cells stained for S100A4 in
the Rbm
To confirm a potential epithelial origin of cells in the
Rbm, bronchial biopsy sections were double stained for
both cytokeratin-(s) (epithelial marker) and S100A4
(mesenchymal marker). This analysis demonstrated that
all cells in the epithelium stained for cytokeratin as
might be expected, while about 13.8% of these stained
for S100A4; all of the S100A4 cells stained for cytokera-
tin-(s) (i.e. the cells exhibited both visualization chromo-
gens). In the Rbm, however, fewer cells (about 7%) were
positive for cytokeratin-(s) but these cells were all dou-
ble-positive for both cytokeratin (s) and S100A4 (Figure
1 and Table 2).
Comparative analysis of S100A4 staining with that for
immune and inflammatory cells
This comparison demonstrated that there were signifi-
cantly more (p < 0.003, for all comparisons, Figure 2
and Table 3) cells stained for S100A4 in the basal
epithelium and Rbm compared to cells specifically
stained for CD4+/CD8+ T lymphocytes, CD19 (B-cells),
CD11c (dendritic cell/inflammatory cell marker), S100
(human Langerhans cell marker, Figure 3), neutrophil
elastase (neutrophil marker) or CD68 (macrophage and
mature fibroblast marker) [21,22].
Discussion
We have previously published that EMT could be an
active process in human smokers’ airways, [7] based on
the demonstration of Rbm fragmentation and cleft for-
mation and the presence of cells in both Rbm and basal
epithelium staining for established markers of EMT
[12,15] such as S100A4 and MMP-9. These changes
were present in airway biopsies from asymptomatic
smokers with normal lung function, but were most pro-
nounced in currently smoking COPD patients. This con-
firmatory study, although with limited numbers,
focussed on this most relevant clinical phenotypic
group, but is likely to be generalizable also to smokers
with normal lung function.
Although we have provided rare, human data in human
COPD, suggesting the potential for EMT, [7] this conclu-
sion has been open to reviewer scepticism that the mar-
kers of EMT that we used, although regarded as ‘classic’ in
Table 1 Demographic details of the subjects who
participated in the current study (n = 6), compared to
the full original population of patient volunteers from
whom they were selected (n = 17)
Group
(numbers)
COPD-CS
(n = 17)
COPD-CS
(n = 6)
GOLD I/GOLD II 10/7 3/3
Male/female 9/8 4/2
Age (Range) 61 (46-78) 59 (55-62)
Smoking pack years (Range) 45 (18-78) 45 (32-70)
FEV1% predicted
(Range)†
83 (66-102) 76 (66-102)
FEV1/FVC%
(Range)†
59 (46-68) 61 (48-68)
Data expressed as medians and ranges. There were no significant difference
between the whole group and the current study subgroups.
† Post BD values after 400μg of inhaled salbutamol
Figure 1 Bronchial biopsy specimen from a COPD current
smoker double-stained for both S100A4 (green) and
cytokeratin (red). Black arrows showing cells in the basal
epithelium and reticular basement membrane (Rbm) and also
within the superficial lamina propria, double-stained for both
cytokeratin (red, anti-pan-cytokeratin monoclonal antibody, epithelial
marker) and S100A4 (green, anti-S100A4 polyclonal antibody,
mesenchymal marker). Overall, there are fewer double-stained cells
in the Rbm than in the basal epithelium; consistent with loss of
epithelial markers as these cells gain mesenchymal markers. Original
magnifications 100 ×/1.30 Oil. Scale bar = 50 μm.
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kers, especially showing that the Rbm cells express epithe-
lial markers as well as mesenchymal markers. It is also
been suggested that the Rbm cell data could be con-
founded by infiltration from below by inflammatory cells,
which could at least potentially be positive for S100A4 and
MMP-9. Our COPD subjects in this study were on as
needed “relief” bronchodilator medication only, and it is
unlikely that the discussed appearances are due to con-
founding by therapy, which we have deliberately tried to
avoid as much as possible.
I nt h ep r e s e n ts t u d yw eh a v ef o l l o w e du po u rp r e v i o u s
findings by demonstrating that cells in the Rbm positive
for mesenchymal markers did frequently stain with an
epithelial marker. Further, the present study illustrates
that there are cells in the Rbm that double stain for cyto-
keratin-(s) and the “EMT marker” S100A4, representing
further evidence of EMT in smoking-related COPD.
Furthermore, our staining of tissue comprehensively for
markers of a variety of inflammatory cells indicates that
our data were not confounded by significant infiltration
of the Rbm by inflammatory or immune cells.
Although only a relatively small number of cells in the
Rbm could be demonstrated to stain with cytokeratin, it
is possible that more (indeed most) of these Rbm cells
are actually of epithelial origin, as it is well documented
Table 2 Quantification of S100A4/cytokeratin stained cells and S100A4/cytokeratin double-stained cells in the basal
epithelium and Rbm; data expressed as medians and ranges
Markers No. of basal epithelial cells stained per mm of Rbm No. of cells staining in Rbm per
mm of Rbm
S100A4 26.6 (21.3 - 37.3) 58.1 (37.3 - 92.6)
Cytokeratin-(s) 191.7 (135.3 - 297.6)* 4.3 (0.3 - 11.6)*
Cytokeratin-(s) & S100A4
double staining
26.6 (21.3 - 37.3) (basal epithelial cells +ve for S100A4 as shown above were
all +ve for Cytokeratin-(s)
5.9 (2.3 - 13.8)
* Cytokeratin versus S100A4, p < 0.003
Figure 2 Bronchial biopsy specimen from a COPD current smoker stained for immune and inflammatory cell markers compared to
S100A4. Black arrows showing cells positive for: (A) CD4 (anti-CD4 monoclonal anti-body); (B) CD8 (anti-CD8 monoclonal antibody); (C) CD68
(anti-CD68 monoclonal antibody; macrophage and mature fibroblast marker); (D) neutrophil elastase (anti-neutrophil elastase monoclonal
antibody; neutrophil marker); (E) CD11c (anti-CD11c monoclonal antibody; dendritic cell/inflammatory cell marker); compared to (F) S100A4 (anti-
S100A4 polyclonal antibody; mesenchymal marker) stained cells, in the basal epithelium and reticular basement membrane (Rbm). There are
many more S100A4 positive cells in the basal epithelium and Rbm compared to cells stained for any inflammatory cell marker. Most of the cells
positive for inflammatory cell markers are in the lamina propria below the Rbm. Original magnifications, × 630. Scale bar = 50 μm.
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epithelial markers as they gain mesenchymal markers.
Therefore, a cell which has gone through a complete
transition will not express epithelial markers. It is, how-
ever, reassuring from the point of view of our hypothesis
about active EMT in the airways in smokers and COPD,
that we have been able to demonstrate at least a reason-
able number of double-stained cells in the Rbm. Simi-
larly, the frequent presence of cells in the basal
epithelium staining for S100A4 is further evidence of
EMT in these COPD airway biopsies. The data are con-
sistent with a model where migratory cells gain the
S100A4 mesenchymal marker early, but then rapidly
loose epithelial markers as they migrate through the
Rbm.
We found that there were very few CD8+ and CD4+ T
lymphocytes and no CD19 B-cells in the Rbm and basal
epithelium. Cells positive for CD19 were mainly in the
lamina propria and hardly detectable in the basal epithe-
lium or Rbm. We also confirmed that our Rbm cellular
S100A4 staining was not confounded by infiltrating den-
dritic cells or Langerhans cells for which sections were
stained for CD11c (dendritic cell/inflammatory cell mar-
ker) [23] and S100 (human Langerhans cell marker) [24].
Although they were certainly present, there were rela-
tively few such cells in the basal epithelium and Rbm
compared to S100A4-stained cells. Most of the cells posi-
tive for the inflammatory cells studied were observed in
the lamina propria below the Rbm, and not in the Rbm
itself. EMT is a process defined by loss of epithelial mar-
kers and gain of mesenchymal markers. A function of
this is that there is no single definitive marker for EMT.
S100A4 is widely published as representing a reasonable
marker for EMT [8-12]. We have also shown that these
S100A4 positive cells in the Rbm also double-stain for
another mesenchymal protein, vimentin, [7] widely used
as an EMT marker [12,15].
EMT has only recently been recognised in the human
lung or airway, [6,8] and now we provide further
confirmatory evidence for its active presence in COPD
airways [7]. However, EMT is well described in lung
embryogenesis, [25] metastatic malignant disease [26]
and as part of the repair process in renal disease follow-
ing tissue injury [27]. Active EMT is indicated by the
degradation of underlying epithelial basement mem-
brane and transition of epithelial cells into mesenchymal
cells with migratory potential, such that they move away
from the epithelium in which they originated into dee-
per tissue [12,15].
Active airway EMT in COPD could potentially relate
to subsequent fibrotic activity in the sub-epithelial tis-
sue, or just reflect severity of COPD pathology. COPD
is a complex disease with physiologically a mixture of a
variable emphysema component and intrinsic airway
narrowing. Pathologically the airways are always abnor-
mal and it is this component we have sampled from
large airway biopsies. Airway obstruction is thought to
be mainly in the small airways, but the pathology affects
the whole bronchial tree [2-5]. There are in fact very
few data available on fibrosis or alterations in fibroblast/
fibrocyte populations in the airway in COPD. Our data
taken together suggest that remodelling changes can be
more exaggerated in established COPD and especially in
current smokers [28,29]. This area of pathology needs
more specific study and remodelling changes need relat-
ing to changes in airway calibre and stiffness. Even if
there are no immediate physiological consequences,
there may well be implication for other COPD-asso-
ciated processes and especially airway malignancy where
t h ec o n c u r r e n c eo fE M Tm a yb eas i g n i f i c a n tp a r to f
tumour pathogenesis.
EMT has been described in metastatic malignant disease
especially when associated with S100A4 expression.
Epithelial cell nuclear expression of S100A4 strongly cor-
relates with both active EMT and metastatic disease in the
oncology literature [8,30,31]. Increased expressions of
S 1 0 0 A 4a n dM M P - 9a r eo b s e r v e di nh u m a nn o n - s m a l l
cell lung cancer (NSCLC) and have significant correlations
Table 3 Quantification of inflammatory cell markers and S100A4-stained cells in the basal epithelium and Rbm; data
expressed as medians and ranges
Markers No. of basal epithelial cells stained per mm of Rbm No. of cells staining in Rbm per mm of Rbm
S100A4 26.6 (21.3 - 37.3) 58.1 (37.3 - 92.6)
CD4 0 (0 - 5.8)* 0 (0 - 4.8)*
CD8 5.7 (0.9 - 9.6)* 0.3 (0 - 3.8)*
CD19 0 (0 - 0)* 0 (0 - 0)*
CD11c 1 (0 - 1.8)* 0 (0 - 0.2)*
CD68 0.3 (0 - 2.1)* 0 (0 - 0.6)*
NE 0 (0 - 0)* 0 (0 - 0)*
S100 0 (0 - 1.1)* 0.1 (0 - 2.7)*
* Each marker versus S100A4, p < 0.003
Sohal et al. Respiratory Research 2011, 12:130
http://respiratory-research.com/content/12/1/130
Page 5 of 7with clinical and biological behaviour of such cancer cells
[8,30,31]. Epidermal growth factor receptor (EGFR) is also
over-expressed in many types of cancers, including
NSCLC and we have shown that this is co-expressed in
the epithelium as part of the whole ‘COPD phenotype sig-
nal’ [7]. It has been shown that clinical responsiveness to
EGFR inhibition using the “biologic” erlotinib is directly
linked to the degree of EMT in NSCLC [28]. Our findings
of smoking-related active EMT may help understanding of
why lung cancer is so common in smokers, but especially
so in those with COPD where we have found EMT to be
most marked.
Our study is of course limited by the fact that it was
carried out in living human subjects and is based on
‘static’ pictures. Further study may require COPD model
systems in animals and/or human cell culture. This
might allow direct, vital imaging to observe dynamic
real-time changes in cell phenotype and cellular migra-
tion during EMT.
It has been argued that Rbm fragmentation in smokers
and COPD biopsies in our studies represents an “arte-
fact” due to tissue processing. Against this is the fact
that clefts contained cells, and also, to some extent ves-
sels [13]. Further, tissues from normal healthy controls
[7] and asthmatics (data not shown) were processed in
exactly the same way, but rarely showed any such Rbm
fragmentation.
Conclusions
In summary, double staining of cells by both epithelial and
mesenchymal markers in both the basal layer of the
epithelium and within the fragmented Rbm is supportive
of our hypothesis that EMT is indeed likely to be an active
process in the airways in smokers, and especially those of
current-smoking COPD patients. We also provided evi-
dence that these S100A4 stained cells are not being con-
fused with infiltrating inflammatory or immune cells. We
conclude that the most likely origin of the S100A4 and
cytokeratin dual positive cells apparent within the Rbm in
COPD is from the airway epithelium, with this represent-
ing additional evidence that EMT may occur.
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